Deruxtecan is an exatecan-derivative topoisomerase I inhibitor.
Deruxtecan is a thiol reactive derivative of DXd that contains enzymatically cleavable peptide linker GGFG.
Trastuzumab Deruxtecan, sold under the brand name Enhertu was approved by US FDA for treating metastatic HER2-postive breast cancer.
This product is a control ADC for any IgG type antibody labeled with Deruxtecan, particularly any ADC made using CellMosaic's Antibody Deruxtecan Conjugation Kit （Cat#： CM11431）.
The product uses a human IgG1 subtype antibody that does not bind to the target.
It has an average of 3-5 Deruxtecan loaded on each antibody and can be used for accessing the effect of Deruxtecan alone （non-specific toxicity）.
The product uses a very low endotoxin level antibody as a starting material （≤0.5 EU/mg by the LAL method）.
The preparation and purification are conducted under a pyrogen free environment.
The product is sold as 1 vial of 100 microgram （Cat# CM51103-100UG）, 1 vial of 500 micrograms （Cat# CM51103-500UG）, or 2 vials of 500 micrograms （Cat# CM51103-1MG）.
